Led · Equity · Sep 2024

Clouds of Care is a Ghent, Belgium–based MedTech company that develops electrophysiology applications and a comprehensive CNS platform to improve care for people with CNS disorders. Its electrophysiology applications are CE-marked and FDA-cleared for clinicians, and it provides solutions for clinical trials and research. The company holds ISO 13485:2016 and ISO 27001:2013 certifications. Leadership includes Eline Van Vlierberghe (CCO), Gregor Strobbe (co-founder, CEO), Pieter van Mierlo (co-founder, CSO), Jeroen Crappé (COO), Caroline Neuray (CMO), and Tom Van Steenkiste (CTO). Clouds of Care intends to use recent funding to invest in technological infrastructure, expand its team of experts, and deepen research and development. The company also leverages a strategic network of partners to support its platform and care initiatives, and has appointed Michel Vounatsos and Yacine Hadjiat to its board.

Participated · Series B · Jan 2023

Synergia Medical is a preclinical medical device company that has developed NAO.VNS, a non‑metal optoelectronic neurostimulator for vagus nerve stimulation to treat drug‑resistant epilepsy. The company is preparing for First‑In‑Human clinical trials planned for early 2024. It is ISO 13485 certified, operational since 2015, and based in Belgium with a staff of 27 focused on preclinical studies, R&D, quality, and regulatory affairs. Synergia holds a portfolio of nine patents in 15 families and is supported by Wallonia Region grants and the European Innovation Council (Accelerator financing). The team includes co‑founders Attila Borbath (CEO) and Pascal Doguet, and the company has both a business‑oriented Board of Directors and a Scientific Advisory Board of experts in neural stimulation and epilepsy. Financially, the company has previously raised funding and uses the recent proceeds to advance toward clinical milestones. Founded in 2013 by Pascal Doguet and Attila Borbath, Synergia Medical develops opto-electronics medical devices for neurostimulation. Its lead product, NAOS, is a small-form, MRI-safe, implanted neurostimulation device targeting drug-resistant epilepsy with additional therapeutic applications. The company is conducting advanced-stage testing of NAOS ahead of a CE mark filing expected in 2019. Synergia intends to use the funding to complete final testing prior to CE mark submission. The company is also preparing for regulatory approval efforts in the United States where neurostimulation use is increasing. The Series A financing strengthens its position to advance regulatory and commercialization milestones.

Participated · Equity · Sep 2021

Sortlist operates a marketplace that matches clients and marketing agencies using a mix of AI-powered technologies, professional networks and peer-to-peer recommendations. The company says its platform speeds up connections and improves matching accuracy while preserving human oversight. Founded in 2014, Sortlist is active in Belgium, France, Spain, Germany and the Netherlands and plans to use new funding to capture the English-speaking market. The team is roughly 100 people and the company reported about 40% revenue growth in the past year. Over the past two years Sortlist has helped more than 2,700 companies in 91 countries find 1,117 qualified marketing agencies. To date the company has raised a total of €13.6 million. Sortlist operates an online platform that helps companies discover marketing, communication and digital agencies. Founded in 2014 and based in Wavre, Belgium, the platform serves businesses in Belgium, the Netherlands, Switzerland, Germany and France and is also present in North America. The platform is available in five languages and the company is now targeting expansion into Spain and Italy. Leadership includes CEO Thibaut Vanderhofstadt, CMO Nicolas Finet, CTO Charles De Groote, and Product Manager Michael Valette. Sortlist raised €2m in funding and intends to use the funds to enhance its team and consolidate its position in Europe. Sortlist operates an online marketplace that helps companies discover and vet marketing and communication agencies, combining discovery with a reputation and review system. The site lists more than 53,000 communication agencies, which can register for free or upgrade to a premium account for greater visibility and extra features. Companies can search by location, type of work, and budget, and Sortlist integrates LinkedIn to show how close an agency is to a business's professional network for validation. The founders built the product from experience running a digital agency and designed it to address discovery shortcomings of LinkedIn and Google. Monetization is through premium subscriptions for agencies, a model the founders viewed as scalable when they launched the service. The company recently raised external funding, indicating early-stage validation of its business model.

Participated · Series B · Jul 2018

Univercells is a B2B bioprocessing company that develops compact, cost-efficient manufacturing technologies including the NevoLine biomanufacturing platform and the scale-X bioreactor portfolio. The company designs its solutions to reduce footprint, capital and operational expenditures for producing biologics and viral products. With support from stakeholders such as the Bill & Melinda Gates Foundation, the Global Health Investment Fund and the European Investment Bank, Univercells aims to increase global access to affordable vaccines, biosimilars and advanced therapies. The new financing will be used to industrialize and commercialize its manufacturing technologies and to drive product and application development. Univercells plans to expand further into the gene therapy segment, enabling best-in-class solutions for viral manufacturing. The company is headquartered in Gosselies, Belgium. Univercells develops compact biomanufacturing platforms aimed at increasing the availability and affordability of biologics, including recombinant proteins and vaccines. Founded in 2013 by Hugues Bultot (CEO) and José Castillo (CTO) and based in Gosselies, Belgium, the company builds technology solutions for vaccines, monoclonal antibodies and enzyme replacement therapies. It intends to commercialize a diversified portfolio of technologies with first products available for human use as soon as 2019. Univercells is concluding technology transfer negotiations with established biologics manufacturers and healthcare providers in China, India and Latin America. The company has received regional support from the Walloon region and prior financing including a €3m seed from Takeda in 2015 and a $16m grant from the Bill & Melinda Gates Foundation at the end of 2016. Univercells is a Gosselies, Belgium-based technology company that develops innovative and cost-effective biomanufacturing solutions. The company designs novel production processes for biologics, including recombinant proteins and vaccines, to significantly decrease the size of required equipment and facilities and lower capital and operational costs. It was founded in 2013 by Hugues Bultot (CEO) and José Castillo (CTO). Univercells will use a €2.4M grant from the Walloon Region to develop its antibody production platform. The program focuses on designing next-generation production technologies to drastically reduce manufacturing costs while producing large quantities. The resulting low-footprint, high-capacity production units are intended to be more affordable to build and operate, improving worldwide access to high-quality biologics. Univercells, founded in 2013 and based in Gosselies, Belgium, develops novel biomanufacturing platforms for recombinant proteins and vaccines. Its core products include a viral micro-facility and an innovative recombinant production platform. The company aims to increase the availability and affordability of biologics through these technologies. Univercells closed a €3m Series A equity round to fund commercial and development activities. Proceeds will support the commercial roll-out of its viral micro-facility and the completion of its recombinant platform. A first technology transfer for the viral micro-facility is anticipated in Q4 2018 within a Bill & Melinda Gates Foundation-supported program. Univercells is a Gosselies, Belgium-based developer of a vaccine manufacturing platform that leverages manufacturing sciences to design biomanufacturing solutions for viral vaccines and recombinant proteins. The company focuses on process intensification and integration technologies to enable local bioproduction facilities. It will use a $12M grant from the Bill & Melinda Gates Foundation to develop a vaccine manufacturing platform aimed at lowering costs and increasing vaccine availability and affordability in developing countries. The development will be performed by a consortium including Batavia Biosciences and Natrix Separations, combining Univercells' process intensification and integration capabilities, Natrix's single-use chromatography membrane platform, and Batavia's vaccine development and manufacturing capabilities. The initial target is a micro-facility for inactivated polio vaccine (sIPV) capable of producing 40 million trivalent doses per year at a manufacturing cost below $0.15 per dose. The company is led by CEO and co-founder Hugues Bultot and CTO and co-founder José Castillo.